WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1993020210) ANTIBODIES FOR TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1993/020210    International Application No.:    PCT/GB1993/000725
Publication Date: 14.10.1993 International Filing Date: 06.04.1993
Chapter 2 Demand Filed:    21.10.1993    
IPC:
A61K 38/00 (2006.01), C07K 14/135 (2006.01), C07K 16/10 (2006.01)
Applicants: SCOTGEN LIMITED [GB/GB]; Queen's House, 2 Holly Road, Twickenham, Middlesex TW1 4EG (GB) (For All Designated States Except US).
TAYLOR, Geraldine [GB/GB]; (GB) (For US Only).
STOTT, Edward, James [GB/GB]; (GB) (For US Only)
Inventors: TAYLOR, Geraldine; (GB).
STOTT, Edward, James; (GB)
Agent: VALENTINE, Jill, Barbara; SmithKline Beecham plc, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB)
Priority Data:
9207479.8 06.04.1992 GB
Title (EN) ANTIBODIES FOR TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION
(FR) ANTICORPS DESTINES AU TRAITEMENT ET A LA PREVENTION DES INFECTIONS DUES AU VIRUS RESPIRATOIRE SYNCYTIAL
Abstract: front page image
(EN)The present invention provides variable light chain and variable heavy chain sequences derived from bovine anti-RSV F protein monoclonal antibodies (mAbs), B4 and B13/B14, and CDR peptides therefrom, which may be employed in the design of fusion proteins (including altered antibodies) which are charaterized by the antigen binding specificity of these mAbs. Also described is a humanized antibody containing bovine variable chain sequences. Methods for producing and using these compositions, including pharmaceutical compositions are disclosed.
(FR)L'invention concerne des séquences variables de chaînes légères et lourdes dérivées d'anticorps monoclonaux (Acm) antiprotéine F du VSR bovin, B4 et B13/B14, et elle concerne aussi les peptides des régions déterminantes de complémentarité (RDC) qui en proviennent. On peut les utiliser pour concevoir des protéines de fusion (y compris des anticorps modifiés) caractérisées par la spécificité de liaison à l'antigène de ces Acm. On décrit aussi un anticorps humanisé qui contient des séquences de chaînes variables bovines. On expose des procédés permettant de produire et d'utiliser de tels composés et aussi des compositions pharmaceutiques.
Designated States: AU, CA, JP, KR, NZ, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)